Clinical and genetic associations with prostacyclin response in pulmonary arterial hypertension-Reference-Cited by-同舟云学术

Clinical and genetic associations with prostacyclin response in pulmonary arterial hypertension

Published:2018-09 Issue:4 Volume:8 Page:1-9
ISSN:2045-8940
Container-title:Pulmonary Circulation
language:en
Short-container-title:Pulm. circ.

Author:

Halliday Stephen J.¹^ORCID,Xu Meng²,Thayer Timothy E.³,Mosley Jonathan D.⁴,Sheng Quanhu⁵,Ye Fei²,Farber‐Eger Eric H.⁶,Pugh Meredith E.¹,Robbins Ivan R.¹,Assad Tufik R.¹,West James D.¹,Brittain Evan L.³⁶,Hemnes Anna R.¹

Affiliation:

1. Division of AllergyPulmonary and Critical Care MedicineVanderbilt University Medical CenterNashvilleTNUSA

2. Department of BiostatisticsVanderbilt University Medical CenterNashvilleTNUSA

3. Division of Cardiovascular MedicineVanderbilt University Medical CenterNashvilleTNUSA

4. Department of Biomedical InformaticsVanderbilt University Medical CenterNashvilleTNUSA

5. Center for Quantitative Sciences, Vanderbilt University Medical CenterNashvilleTNUSA

6. Center for Translational and Clinical Cardiovascular ResearchVanderbilt University Medical CenterNashvilleTNUSA

Funder

National Institutes of Health

American Heart Association

National Heart, Lung, and Blood Institute

Gilead Sciences

Publisher

Wiley

Subject

Pulmonary and Respiratory Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1177/2045894018800544

Reference39 articles.

1. Five‐Year outcomes of patients enrolled in the REVEAL Registry;Farber HW;Chest,2015

2. 2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension: The Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS): Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC), International Society for Heart and Lung Transplantation (ISHLT);Galie N;Eur Heart J,2016

3. Survival in primary pulmonary hypertension: the impact of epoprostenol therapy;McLaughlin VV;Circulation,2002

4. A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension;Barst RJ;N Engl J Med,1996

5. Identifying “super responders” in pulmonary arterial hypertension;Halliday SJ;Pulm Circ,2017

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Multifunctional nanoparticle-mediated combining therapy for human diseases;Signal Transduction and Targeted Therapy;2024-01-01

2. Metabolic syndrome, neurohumoral modulation, and pulmonary arterial hypertension;British Journal of Pharmacology;2020-02-18

3. Parenteral Prostacyclin Use in Pulmonary Arterial Hypertension;Pulmonary Hypertension;2020

4. Total synthesis of PGF2α and 6,15-diketo-PGF1α and formal synthesis of 6-keto-PGF1α via three-component coupling;Tetrahedron;2019-10